After several years of witchhunting, can calcium-based phosphate binding be released on probation?

Abstract

37. Karle SM, Uetz B, Ronner V et al. Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2002; 13: 388–393 38. Oleggini R, Bertelli R, Di Donato A et al. Rare functional variants of podocin (NPHS2) promoter in patients with nephrotic syndrome. Gene Expr 2006; 13: 59–66 39. Van Der Berg J, Weening JJ. Role of the immune system in the pathogenesis of the idiopathic nephrotic syndrome. Clin Sci 2004; 107: 125–136 40. Grimbert P, Audard V, Valancuite A et al. Abnormal RNA processing and altered expression of serine-rich proteins in minimal change nephrotic syndrome. Pediatr Res 2005; 57: 133–137 41. Mansour H, Cheval L, Elalouf JM et al. T-cell transcriptome analysis points up a thymic disorder in idiopathic nephrotic syndrome. Kidney Int 2005; 67: 2168–2177 42. Kimata H, Fujimoto M, Furusho K. Involvement of interleukin (IL)13, but not IL-4, in spontaneous IgE and IgG4 production in nephrotic syndrome. Eur J Immunol 1995; 25: 1497–14501 43. Yap HK, Cheung W, Murugasu B et al. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL13 mRNA expression in relapse. J Am Soc Nephrol 1999; 10: 529–537 44. Kolstad A, Holte H, Fossa A et al. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007; 92: 139–140 45. Wong CF, Corbett S, Darroch J et al. Rituximab and refractory ANCA associated vasculitis; is low CD4 count detrimental? Abstract in Renal Association and British Renal Society, Harrogate, UK, May 2006 46. Quartier P, Brethon B, Philippet P et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001; 358: 1511–1513 47. Kemper MJ, Moller K, Lugwig K et al. Rituximab in treatment of refractory steroid sensitive nephrotic syndrome (abstract). Pediatr Nephrol 2006; 21: 1528 48. FDA Public Health Advisory. Life-threatening brain infection in patients with Systemic Lupus Erythematosus after Rituxan (Rituximab) treatment 2006 http://www.fda.gov/cder/drug/advisory/rituximab. htm 49. Jillella AP, Dainer PM, Kallab AM et al. Treatment of a patient with end stage renal disease with rituximab: pharmacokinetic evaluation suggests rituximab is not eliminated by haemodialysis. Am J Haematol 2002; 71: 219–222